1. Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR;
2. Celgene Corporation, San Francisco, CA;
3. Cancer Research and Biostatistics, Seattle, WA;
4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
5. Celgene Corporation, Summit, NJ;
6. Celgene Institute of Translational Research Europe, Sevilla, Spain;
7. Rancho BioSciences, San Diego, CA;
8. Multiple Myeloma Research Foundation, Norwalk, CT;
9. Translational Genomics Research Institute, Phoenix, AZ;
10. Department of Oncology, University of Milan, Milan, Italy;
11. Department of Hematology, University of Nantes, Nantes, France;
12. Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA;
13. Department of Hematology, Mayo Clinic, Scottsdale, AZ;
14. Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany;
15. German Cancer Research Center, Heidelberg, Germany;
16. Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany;
17. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
18. Centro Investigacion Medica Aplicada, Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Oncología, Pamplona, Spain;
19. Winship Cancer Institute, Emory University, Atlanta, GA;
20. Department of Haematology, Newcastle University, Newcastle, United Kingdom;
21. Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale U1037, Toulouse, France; and
22. L’Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France